Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

This study found that using spanlastics, a nano, surfactant-based drug delivery system, improved the bioavailability, drug release characteristics, and pharmacokinetic behavior of famotidine, a poorly soluble drug, by enhancing its dissolution and membrane permeation.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.

This review outlines drug repurposing as an efficient, low-cost strategy to identify new uses for existing drugs, highlighting various computational and experimental approaches as well as publicly available databases to aid in personalized pharmacotherapy.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

Finasteride solution helps treat hair loss.

This study found that women with PCOS displayed significantly higher activity of 5alpha-reductase, suggesting an additional role for liver and peripheral tissues in their androgen excess.

This study found that women with PCOS have higher activity of the enzyme 5alpha-reductase, which may contribute to their elevated androgen levels.

This study found that a testosterone patch and gel showed bioequivalent testosterone levels in hypogonadal men, but the patch mimicked a natural circadian profile, while the gel resulted in higher dihydrotestosterone levels.

This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that a 5-mg daily dose of transdermal testosterone cream in postmenopausal women restored testosterone levels to those typical of premenopausal women.

This study found that type 2 diabetes mellitus does not affect the pharmacokinetics of metformin in obese pregnant women with PCOS, suggesting no need for dosage adjustments.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This study found that an oral testosterone formulation normalized serum testosterone levels and significantly reduced SHBG in men with experimentally induced hypogonadism after nine days of treatment, suggesting potential efficacy for testosterone deficiency.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.

Finasteride interacts with terazosin, but not doxazosin; caution needed.

This study observed significant clinical effects, such as hair loss and testicular changes, in common quail treated with the steroids IVF-C Inj and Diane-35, especially highlighting cyproterone acetate's impact on vital organs like the liver.

This study reported that continuous intravenous dextran sulfate was toxic and ineffective as a treatment for symptomatic HIV infection, as it did not improve surrogate markers and caused significant side effects.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

This study analyzed data from 2083 patients with alopecia areata in Europe and found that those with atopic, autoimmune, or psychiatric comorbidities encountered more severe disease and were more likely to require advanced treatments compared to those without comorbid conditions.

Minoxidil treats high blood pressure and side effects can be managed.

This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.